Summit Therapeutics (SMMT) Return on Capital Employed: 2017-2024
Historic Return on Capital Employed for Summit Therapeutics (SMMT) over the last 2 years, with Dec 2024 value amounting to -0.42%.
- Summit Therapeutics' Return on Capital Employed rose 7.00% to -0.42% in Q4 2024 from the same period last year, while for Dec 2024 it was -0.42%, marking a year-over-year increase of 7.00%. This contributed to the annual value of -0.81% for FY2024, which is 66.00% up from last year.
- As of Q4 2024, Summit Therapeutics' Return on Capital Employed stood at -0.42%, which was down 13.45% from -0.37% recorded in Q3 2024.
- Summit Therapeutics' 5-year Return on Capital Employed high stood at -0.14% for Q4 2022, and its period low was -0.57% during Q3 2023.
- Moreover, its 3-year median value for Return on Capital Employed was -0.40% (2024), whereas its average is -0.40%.
- As far as peak fluctuations go, Summit Therapeutics' Return on Capital Employed crashed by 35bps in 2023, and later increased by 20bps in 2024.
- Quarterly analysis of 4 years shows Summit Therapeutics' Return on Capital Employed stood at -0.32% in 2020, then reached -0.14% in 2022, then crashed by 35bps to -0.49% in 2023, then climbed by 7bps to -0.42% in 2024.
- Its last three reported values are -0.42% in Q4 2024, -0.37% for Q3 2024, and -0.49% during Q4 2023.